Meiragtx Holdings Plc (MGTX) valuation
Meiragtx Holdings Plc P/E ratio history
Meiragtx Holdings Plc trades at 13.4 times its earnings over the last twelve months.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $7.95 | -$1.42 | n/m |
| Dec 31, 2024 | $6.09 | -$2.12 | n/m |
| Dec 31, 2023 | $7.02 | -$1.49 | n/m |
| Dec 31, 2022 | $6.52 | -$2.87 | n/m |
| Dec 31, 2021 | $23.74 | -$1.80 | n/m |
| Dec 31, 2020 | $15.14 | -$1.54 | n/m |
| Dec 31, 2019 | $20.02 | -$1.67 | n/m |
| Dec 31, 2018 | $9.64 | -$5.37 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Meiragtx Holdings Plc valuation against its peers
| Company | Market value | Price / sales |
|---|---|---|
| Meiragtx Holdings PlcMGTX | $879M | 2.2 |
| Aktis OncologyAKTS | $881M | — |
| CryoportCYRX | $871M | 4.7 |
| AlumisALMS | $858M | 116.0 |
| VerastemVSTM | $857M | 9.8 |
| QuidelorthoQDEL | $904M | 0.3 |
| StriveASST | $905M | — |
| Prime MedicinePRME | $853M | 209.4 |
| Monte Rosa TherapeuticsGLUE | $909M | 31.6 |
| Peer median | 20.7 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: MGTX financials · MGTX returns
No forecast, no recommendation. This page describes Meiragtx Holdings Plc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.